SIGEMSO
pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, diseases and disorders of the endocrine system, inflammatory diseases and disorders, autoimmune diseases and disorders, cancer, neurological diseases and disorders, central nervous system diseases and disorders, acute organ injury, epigenetic diseases and disorders, and DNA methyltransferase (DNMT)-associated diseases and disorders
Abandoned · June 13, 2020 · 90000193 ·